CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.
Analysts were impressed with Almirall SA’s first-half sales, noting the strong launch of the oral acne antibiotic Seysara in the US. CEO Peter Guenter told Scrip the firm had “executed well on the new, more ambitious agenda” to focus on “meaningful and clinically relevant innovation” in dermatology.
Guenter, who took over as CEO in October 2017, has accelerated and sharpened the company’s focus on dermatology, committing to...
A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.
Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.
